Analyst Price Targets — AGIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 12, 2026 4:40 pm | Greg Renza | Truist Financial | $39.00 | $28.42 | StreetInsider | Agios Pharma (AGIO) PT Raised to $39 at Truist Securities |
| December 26, 2025 11:26 am | — | Leerink Partners | $40.00 | $29.17 | TheFly | Agios Pharmaceuticals price target raised to $40 from $34 at Leerink |
| December 24, 2025 5:29 pm | — | H.C. Wainwright | $62.00 | $29.17 | TheFly | Agios Pharmaceuticals price target raised to $62 from $48 at H.C. Wainwright |
| December 24, 2025 4:55 pm | Gregory Renza | Truist Financial | $38.00 | $29.17 | TheFly | Agios Pharmaceuticals price target raised to $38 from $32 at Truist |
| November 24, 2025 12:25 pm | — | Truist Financial | $32.00 | $25.24 | TheFly | Agios Pharmaceuticals initiated with a Buy at Truist |
| November 20, 2025 11:34 am | — | Goldman Sachs | $25.00 | $25.55 | TheFly | Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs |
| November 20, 2025 11:26 am | — | Leerink Partners | $34.00 | $22.34 | TheFly | Leerink upgrades Agios to Outperform after 51% pullback |
| October 20, 2025 10:42 am | Emily Bodnar | H.C. Wainwright | $56.00 | $42.33 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO) |
| May 2, 2025 1:25 pm | Greg Harrison | Scotiabank | $71.00 | $30.10 | TheFly | Agios Pharmaceuticals price target lowered to $71 from $74 at Scotiabank |
| October 31, 2024 5:16 pm | Danielle Brill | Raymond James | $51.00 | $44.43 | StreetInsider | Raymond James Reiterates Outperform Rating on Agios Pharma (AGIO) |
Latest News for AGIO
PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge Pharmaceuticals, a regional specialty company, will continue to manage commercialization of PYRUKYND in the Gulf region CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company…
Rock Springs Capital Management sold 159,379 Agios Pharmaceuticals shares in the fourth quarter; the estimated trade size was $5.59 million based on average fourth-quarter prices. Meanwhile, the quarter-end position value decreased by $16.72 million, reflecting both share sales and price movements.
AGIO beats fourth-quarter estimates for both the top and bottom lines as Pyrukynd sales jump 49% year over year.
Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $1.97. This compares to a loss of $1.74 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AGIO.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.